Instructions for Troxevasin gel 2% tube 100 g
Composition
active ingredient: troxerutin;
1 g of gel contains 20 mg of troxerutin;
Excipients: carbomer, triethanolamine, disodium EDTA, benzalkonium chloride, purified water.
Dosage form
Gel 2%.
Main physicochemical properties: gel from yellow to light brown in color.
Pharmacotherapeutic group
Angioprotectors. Capillary stabilizing agents. Bioflavonoids. Troxerutin. ATC code C05C A04.
Pharmacological properties
Pharmacodynamics
Troxevasin® is a mixture of bioflavonoids containing at least 95% troxerutin. Troxerutin accumulates selectively in the endothelial layer of venules, penetrates deeply into the subendothelial layer of the venous wall, and the concentration is higher than in neighboring tissues. The drug prevents damage to cell membranes caused by oxidation.
The antioxidant effect is manifested in the reduction and elimination of the oxidative properties of oxygen, inhibition of lipid peroxidation, protection of the vascular endothelium from the oxidative action of hydroxyl radicals. Troxerutin reduces the increased permeability of capillaries and has a venotonic effect. The cytoprotective effect is the result of inhibition of neutrophil activation and adhesion, reduction of erythrocyte aggregation and increase of erythrocyte resistance to deformation, reduction of the release of inflammatory mediators.
Increases venous-arterial reflux, prolongs venous refill time, improves microcirculation and microvascular perfusion.
The action of the drug Troxevasin® is aimed at reducing swelling, pain, improving trophism and eliminating various pathological disorders associated with venous insufficiency.
Pharmacokinetics
After topical application of Troxevasin® gel, the active ingredient is easily released from the water-soluble gel base and penetrates the dermis after approximately 30 minutes, and into the subcutaneous fatty tissue after 2-5 hours.
Indication
Troxevasin®, gel, is used for the symptomatic treatment of the following diseases:
venous insufficiency;
prevaricose and varicose syndrome;
superficial thrombophlebitis, phlebitis and post-phlebitic conditions;
comprehensive treatment of hemorrhoidal disease;
muscle cramps (convulsive contraction of the calf muscles).
Contraindication
Hypersensitivity to troxerutin or to any of the excipients of the medicinal product. Troxevasin® gel should not be applied to mucous membranes, open wounds and eczematous skin areas.
Interaction with other medicinal products and other types of interactions
The drug enhances the effect of ascorbic acid on strengthening the structure and reducing the permeability of the vascular wall.
Application features
Hypersensitivity reactions are more common in patients with skin and/or allergic diseases.
Benzalkonium chloride, which is part of the drug, has an irritating effect and may cause skin reactions. Troxevasin® gel should not be used in the eyes or on inflamed skin.
Patients with severe renal impairment are not recommended to use the drug for a long time.
If the severity of the symptoms of the disease does not decrease when using the drug, you should consult a doctor.
Use during pregnancy or breastfeeding
There is no data on the negative effects of the drug when used during pregnancy or breastfeeding. However, the use of Troxevasin® gel in the first trimester of pregnancy is not recommended. This drug should not be applied to the mammary glands of nursing mothers, as it can enter the child's body during breastfeeding.
The ability to influence the reaction speed when driving or working with other mechanisms
Does not affect.
Method of administration and doses
For skin use only.
Apply the gel to the affected area with an even thin layer 2 times a day (morning and evening), rubbing in with light massage movements until the drug is completely absorbed. If necessary, you can apply a tight or elastic bandage. The gel is odorless and does not leave greasy stains on clothes. In severe conditions, combination therapy with Troxevasin® capsules is recommended. In chronic venous insufficiency, use combination therapy until the symptoms disappear completely.
The dosage and duration of use of the drug is determined by the doctor, taking into account the severity and course of the disease.
Children
There are no contraindications for the use of the drug in children.
Overdose
With local application, cases of overdose of the drug have not been registered. In case of accidental ingestion of a large amount of the drug, general measures should be taken to eliminate the drug (for example, induce vomiting) and symptomatic treatment should be applied. If necessary, peritoneal dialysis should be performed.
Side effects
When using Troxevasin® gel, skin irritation or allergic reactions may very rarely occur, including redness, itching, skin rash, dermatitis, angioedema. Usually, these symptoms quickly disappear after discontinuation of the drug.
Reporting of suspected adverse reactions. All cases of suspected adverse reactions and lack of efficacy of the drug should be reported via the link: https://aisf.dec.gov.ua/.
Expiration date
5 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Do not freeze!
Keep out of reach of children.
Packaging
20 g, 40 g, or 100 g in tubes. One tube in a cardboard pack.
Vacation category
Without a prescription.
Producer
Balkanfarma-Troyan JSC.
Location of the manufacturer and address of its place of business
1 Krayrechna St., Troyan, 5600, Bulgaria.
